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1. Introduction {#prca1926-sec-0050}
===============

Hepatitis B virus (HBV) is the prototypic member of the *Hepadnaviridae* family, which contains a group of closely related hepatotropic small DNA viruses with pronounced host specificity.[1](#prca1926-bib-0001){ref-type="ref"} The HBV genome is a 3.2 kb, circular, partially double‐stranded DNA with four open reading frames (ORFs) named pre‐C/C, pre‐S/S, P, and X. The pre‐C/C ORF encodes the hepatitis B e antigen (HBeAg) and hepatitis B core antigen (HBcAg); the pre‐S/S ORF encodes the hepatitis B surface antigen (HBsAg); the P gene encodes the viral polymerase; the X gene encodes a nonstructural protein known as hepatitis B virus X‐protein (HBx).[2](#prca1926-bib-0002){ref-type="ref"} HBx is a 154‐amino acid protein with an N‐terminal negative regulatory domain and a C‐terminal transactivation or coactivation domain. HBx is a multifunctional regulator that modulates gene transcription, signaling pathways, genotoxic stress responses, protein degradation, cell cycle, cell proliferation, and apoptosis and genetic stability by directly or indirectly interacting with host factors.[3](#prca1926-bib-0003){ref-type="ref"}

The role of HBx in the viral life cycle has been investigated by several studies. It has been demonstrated that X‐deficient hepadnaviral genomes inoculated into woodchuck livers are unable to initiate productive infections.[4](#prca1926-bib-0004){ref-type="ref"} Moreover, the role of HBx in activating HBV transcription and replication has been recently demonstrated using cellular systems and mouse models. HBx could restore HBV transcription and replication with the X‐deficient replicon to wild‐type levels in vivo and in vitro.[1](#prca1926-bib-0001){ref-type="ref"}, [5](#prca1926-bib-0005){ref-type="ref"}, [6](#prca1926-bib-0006){ref-type="ref"}, [7](#prca1926-bib-0007){ref-type="ref"} To further investigate the precise regions of HBx involved in the stimulation of HBV transcription and replication, a study performed by Tang et al. constructed a series of clustered alanine substitution mutants (Cm1--Cm21) of HBx using an alanine scanning mutagenesis strategy. For each mutant, seven consecutive amino acids were replaced by the sequence AAASAAA. The HBx mutants Cm1--Cm7 and Cm10--Cm12 (2--50 aa, 67--87 aa) retained the ability to complement the augmentation effect of HBx on HBV replication. HBx mutants Cm8--Cm9 and Cm13--Cm21 (52--65 aa, 88--154 aa) were unable to restore the augmentation function of HBx.[7](#prca1926-bib-0007){ref-type="ref"}, [8](#prca1926-bib-0008){ref-type="ref"} It was also found that the transactivation and coactivation activities of HBx coincide well with its augmentation function in HBV transcription and replication.[7](#prca1926-bib-0007){ref-type="ref"} Therefore, the regions spanning aa 52--65 and aa 88--154 of HBx are important for the transactivation or coactivation activities of HBx and its stimulatory function in HBV transcription and replication.

Clinical relevance {#prca1926-sec-0060}
------------------

HBx plays an important role in augmenting HBV replication by the transcriptional transactivation function in vivo and in vitro. However, the underlying molecular mechanism by which HBx enhances HBV replication is not fully understood. The transcriptional transactivation function of HBx is dependent on pleiotropic protein--protein interactions. The "key" host proteins involved in HBx enhancement of HBV transcription and replication have not been identified. Clarification of the roles of the host proteins in HBx argumentation of HBV transcription and replication would help to elucidate the HBV pathogenicity mechanism. In this study, we utilized iTRAQ proteomic methodology coupled with LC‐ESI‐MS/MS to identify and quantitate differentially expressed proteins among HepG2 cell lines stably harboring different functional domains of HBx. RSK2 was identified as a novel host protein that plays a role in HBx augmenting HBV replication based on iTRAQ quantitative comparative proteomics. This result may help to better understand the HBV pathogenicity mechanism and may provide new therapy targets for HBV replication.

Although the first activity identified for HBx was the ability to activate transcription of viral and cellular genes, HBx is unable to directly bind to any HBx‐responsive elements in viral and host genes. The trans‐acting transcriptional activity of HBx in enhancing HBV replication may depend on protein--protein interactions. The regulation of transactivation activity by HBx relies on the interactions with several components of the basal transcriptional machinery, cellular sequence‐specific transcription factors, or activation of signal transduction pathways.[9](#prca1926-bib-0009){ref-type="ref"} However, the underlying molecular mechanism of HBx activating HBV replication are not fully understood. The "key" host proteins involved in HBx activating HBV transcription and replication are not fully understood.

Isobaric tags for relative and absolute quantitation (iTRAQ) coupled with liquid chromatography coupled with tandem mass spectrometry (LC‐MS/MS) is a powerful proteomics technique for quantifying protein changes. ITRAQ technology has many advantages compared with 2D gel electrophoresis, including high‐throughput capabilities and identification of low‐abundance proteins. The advantages of iTRAQ have made it applicable for investigating the underlying molecular mechanisms in many types of scientific research.

To elucidate the molecular mechanisms of HBx regulation of HBV replication, we utilized iTRAQ proteomic methodology coupled with LC‐MS/MS to identify and quantitate proteins that are differentially expressed in HepG2 cells lines stably harboring different functional domains of HBx. In addition, our approach led to the identification of p90 ribosomal S6 kinase 2 (RSK2), which was found to be highly expressed in HepG2 cell lines stably harboring functional domain of HBx. In addition, the role of RSK2 in HBx enhancement of HBV transcription and replication was investigated.

2. Experimental Section {#prca1926-sec-0070}
=======================

2.1. Plasmid Constructions {#prca1926-sec-0080}
--------------------------

The plasmid payw1.2 (1.2wt, subtype ayw) has been described previously,[7](#prca1926-bib-0007){ref-type="ref"} and contains 1.2 copies of the wild‐type HBV genome. The HBx‐minus mutant vector payw\*7(1.2x(‐)) contains 1.2 copies of HBx‐minus HBV genome.[7](#prca1926-bib-0007){ref-type="ref"}

The mammalian expression plasmids pNKF‐HBx expresses full‐length HBx (aa 1--154). Alanine scanning mutagenesis was employed to construct a series of clustered alanine substitution mutants (designated Cm) as previously described.[7](#prca1926-bib-0007){ref-type="ref"} The pNKF‐Xcm6 plasmid that expresses HBx with a 7‐aa residue mutant retained the ability to complement the augmentation effect of HBx (aa 37--43 was changed to AAASAAA). The pNKF‐Xcm16 plasmid that expresses HBx with a 7‐aa residue mutant was unable to complement the augmentation effect of HBx (aa 101--108 changed to AAASAAA).

The mammalian expression plasmids pcDNA3.1‐HBx, pcDNA3.1‐Xcm6, and pcDNA 3.1‐Xcm16 were derived from pNKF‐HBx, pNKF‐Xcm6, and pNKF‐Xcm16, respectively. The forward primer contained an EcoRI site (5'‐TACGAATTCATGGCTGCTAGGG TGTGC‐3'), and the reverse primer contained an Xba I site (5'‐GCGTCTAGATTAGGCAGAGGTGAAAAAGTTGC‐3').

2.2. Cell Culture {#prca1926-sec-0090}
-----------------

The human hepatocellular carcinoma HepG2 cells were cultured in DMEM with 10% fetal bovine serum, 1 mM glutamate, and100 units mL^−1^ penicillin and were maintained at 37 °C in a 5% CO~2~--air mixture incubator. The stable HBV replication cell line HepG2.2.15 was cultured in DMEM with 100 μg mL^−1^ G418. HepG2 cells that constitutively express X‐wt, X‐cm6, and X‐cm16 were prepared by transfection with pcDNA3.1‐HBx, pDNA3.1‐Xcm6 and pDNA3.1‐Xcm16, respectively. Stably transfected cells were selected in the presence of 400 μg mL^−1^ geneticin for 2--3 weeks. HepG2‐HBx‐Cm6 retained the ability to complement the augmentation effect, whereas HepG2‐HBx‐Cm16 did not.

2.3. Protein Sample Preparation {#prca1926-sec-0100}
-------------------------------

The cells were suspended in the lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 40 mM tris‐HCl, pH 8.5, 1 mM PMSF, and 2 mM EDTA) and were sonicated on ice. The proteins were reduced with 10 mM DTT (final concentration) at 56 °C for 1 h and then were alkylated with 55 mM IAM (final concentration) in the dark for 1 h. The reduced and alkylated protein mixtures were precipitated by adding a 4 × volume of chilled acetone and incubating at −20 °C overnight. After centrifugation at 30 000 g at 4 °C, the pellet was dissolved in 0.5 M TEAB (Applied Biosystems, Milan, Italy) and sonicated on ice. After centrifugation at 30 000 g at 4 °C, an aliquot of the supernatant was taken for determination of protein concentration. The proteins in the supernatant were kept at −80 °C for further analysis.

2.4. iTRAQ Labeling and SCX Fractionation {#prca1926-sec-0110}
-----------------------------------------

Total protein (100 μg) each sample was digested with Trypsin Gold (Promega, Madison, WI, USA) at 37 °C for 16 h with the ratio of protein:trypsin = 30:1. After trypsin digestion, peptides were dried by vacuum centrifugation. Peptides were reconstituted in 0.5 M TEAB and processed according to the manufacture\'s protocol with 8‐plex iTRAQ reagent (Applied Biosystems). Briefly, one unit of iTRAQ reagent was thawed and reconstituted in 24 μL isopropanol. Samples were labeled with the iTRAQ tags as follows: Sample X‐wt (119,121 tag), Sample X‐Cm6 (113,115 tag), and X‐Cm16 (116,117 tag). Peptides were labeled with the isobaric tags, and were incubated at room temperature for 2 h. The labeled peptide mixtures were then pooled and dried by vacuum centrifugation.

SCX chromatography was performed with an LC‐20AB HPLC Pump system (Shimadzu, Kyoto, Japan). The iTRAQ‐labeled peptide mixtures were reconstituted with 4 mL buffer A (25 mM NaH~2~PO~4~ in 25% ACN, pH 2.7) and loaded onto a 4.6 × 250 mm Ultremex SCX column containing 5 μm particles (Phenomenex). The peptides were eluted at a flow rate of 1mL min^−1^ with a gradient of buffer A for 10 min, 5--60% buffer B (25 mM NaH~2~PO~4~, 1 M KCl in 25% ACN, pH 2.7) for 27 min, 60--100% buffer B for 1 min. The system was then maintained at 100% buffer B for 1 min before equilibrating with buffer A for 10 min prior to the next injection. Elution was monitored by measuring the absorbance at 214 nm, and fractions were collected every 1 min. The eluted peptides were pooled into 20 fractions, desalted with a Strata X C18 column (Phenomenex) and vacuum dried.

2.5. LC‐ESI‐MS/MS Analysis Based on Triple TOF 5600 {#prca1926-sec-0120}
---------------------------------------------------

Each fraction was resuspended in buffer A (5% ACN, 0.1%FA) and centrifuged at 20 000 g for 10 min; the final concentration of peptide averaged approximately 0.5 μg μl^−1^. And 10 μL supernatant was loaded onto an LC‐20AD nano HPLC (Shimadzu, Kyoto, Japan) by the autosampler onto a 2 cm C18 trap column. Peptides were eluted onto a 10 cm analytical C18 column (inner diameter 75 μm) packed in‐house. The samples were loaded at 8 μL min^−1^ for 4 min, then the 35 min gradient was run at 300 nL min^−1^ starting from 2 to 35% B (95%ACN, 0.1%FA), followed by 5 min linear gradient to 60%, then, followed by 2 min linear gradient to 80%, and maintenance at 80% B for 4 min, and finally return to 5% for 1 min.

Data acquisition was performed with a TripleTOF 5600 System (AB SCIEX, Concord, ON) fitted with a Nanospray III source (AB SCIEX, Concord, ON) and a pulled quartz tip as the emitter (New Objectives, Woburn, MA). Data were acquired using an ion spray voltage of 2.5 kV, curtain gas of 30 psi, nebulizer gas of 15 psi, and an interface heater temperature of 150 °C. The MS was operated with an RP greater than or equal to 30 000 FWHM for TOF MS scans. Information‐dependent acquisition survey scans were acquired at 250 ms and as many as 30 product ion scans were collected if exceeding a threshold of 120 counts per second with a 2+ to 5+ charge state. Total cycle time was fixed at 3.3 s. The Q2 transmission window was 100 Da for 100%. Four‐time bins were summed for each scan at a pulser frequency of 11 kHz by monitoring of the 40 GHz multichannel TDC detector with four‐anode channel detection. A sweeping collision energy setting of 35 ± 5 eV coupled with iTRAQ adjust rolling collision energy was applied to all precursor ions for collision‐induced dissociation. Dynamic exclusion was set for 1/2 of peak width (15 s), and then the precursor was refreshed off the exclusion list.

ITRAQ‐based quantitative comparative proteomics were completed by the Beijing Genomics Institute. Protein identification was performed using the Mascot search engine (Matrix Science, London, UK; version 2.3.02). To reduce the probability of false peptide identification, only peptides with significance scores (≥ 20) at the 99% confidence interval by a Mascot probability analysis greater than "identify" were counted as identified. Each confidence protein identification involves at least one unique peptide.

2.6. Bioinformatic Analysis {#prca1926-sec-0130}
---------------------------

For protein quantitation, it was required that a protein contains at least two unique peptides. The quantitative protein ratios were weighted and normalized by the median ratio in Mascot. We only used ratios with *p*‐values \< 0.05, only fold changes of **\>** 1.5, and double repetition was considered significant.

Functional annotations of proteins were conducted using the Blast2 GO program against the nonredundant protein database (NR; NCBI). The KEGG database (<http://www.genome.jp/kegg/>) and the COG database (<http://www.ncbi.nlm.nih.gov/COG/>) were used to classify and group identified proteins.

2.7. Real‐Time Quantitative RT‐PCR Analysis {#prca1926-sec-0140}
-------------------------------------------

Total RNA was extracted using Trizol reagent (Invitrogen, IL, USA). One microgram of RNA was reversed‐transcribed into cDNA with a reverse transcription kit (Takara, Japan). Quantitative RT‐PCR was performed on the LightCycler 96 System (Roche, Germany) and using the FastStart Essential DNA Green Master (Roche, Germany) according to the manufacturer\'s instructions. Primers are listed in Table [1](#prca1926-tbl-0001){ref-type="table-wrap"}.

###### 

Primer sequences used in the quantitative RT‐PCR analysis

  Gene      Forward primer                  Reverse primer
  --------- ------------------------------- -------------------------------
  ADH4      5'‐TCCAGAGGAGCTA ATAATCGG‐3'    5'‐AAAGGCAGGGTATGGGTCA‐3'
  SOD1      5'‐GGTCCTCACTTTAATCCTCTATC‐3'   5'‐TTCTTCATTTCCACCTTTGC‐3'
  CSTB      5'‐TACCAAGACCCA GCCCAACT‐3'     5'‐GCCAAGGCACAGCGTAGAT‐3'
  ACSL4     5'‐ GGCATTCCTCCAAGTAGACC‐3'     5'‐CATGA GCCAAAGGCAAGT‐3'
  PLIN2     5'‐ GACTGCCTATTC TGAATCAG‐3'    5'‐CACTGCCCCTTTGGTCTTGT‐3';
  APOA1     5'‐GGCATTTCTGGCAGCAAGAT‐3'      5'‐GGAGC TTAGGTTTAGCTGT‐3'
  RSK2      5'‐CGTGGCAGAAGATGGCTGTG‐3'      5'‐CTGCCTTTTCATGTCCTTCCT‐3'
  PRKAR1A   5'‐AAGGTAGGAGGCGA CGAG‐3'       5'‐GCGATAAAGGAGACCGAA A‐3'
  RRP1B     5'‐CTCCAGTTTGACTATAAGGCT‐3';    5'‐GAGAGGCGCTTCCTGTTGAA‐3'
  DPP4      5'‐ AAGGCACCTGGGAAGTCA‐3'       5'‐GCTCACAACTGAGGCAT G‐3'
  FABP1     5'‐ GGCAAGTACCAACTGCAGAG‐3'     5'‐ CTTGAAGTGCTTCCCATTCT‐3'
  HBcAg     5'‐CTGGGTGGGTGTTAATTTGG‐3'      5'‐TAAGCTGGAGGAGTGCGAAT5'--3'
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2.8. Western Blotting {#prca1926-sec-0150}
---------------------

The cells were lysed at 4 °C in lysis buffer (20 mM tris‐HCl, pH 7.6, 0.5% NP‐40, 250 mM NaCl, 3 mM EGTA, 3 mM EDTA, 1 mM sodium vanadate,2 mM dithiothreitol, 0.5 mM PMSF, 20 mM β‐glycerophosphate, and 1 μg mL^−1^ leupeptin).

The protein samples (20 μg) were separated by 10% SDS‐polyacrylamide gel electrophoresis and transferred to PVDF membrane, and proteins were detected by Western blot.

2.9. Enzyme‐Linked Immunosorbent Assay (ELISA) {#prca1926-sec-0160}
----------------------------------------------

HBsAg and HBeAg in the cell culture medium and mouse serum were measured by using ELISA kits (Kehua Bioengineering, Shanghai, China). HepG2.2.15 and HepG2 cells were seeded in 6‐well plates at 70--80% confluence. After the cells were cultured for 24 h, they were transfected as indicated in the Figure[4](#prca1926-fig-0004){ref-type="fig"} legend. The culture media was collected, and the levels of HBsAg and HBeAg were measured according to the manufacturer\'s instructions.

2.10. Southern Blotting {#prca1926-sec-0170}
-----------------------

The isolation and determination of HBV DNA replication intermediates were performed as previously described. These HBV DNA replication intermediates (HBV DNA RI) were resuspended in 30 μL of tris‐ethylene diamine tetraacetic acid buffer. The samples were separated by 1% agarose and transferred to Hybond‐N+ membrane (Amersham Biosciences, Bucks, UK). The membrane were probed with digoxigenin‐labeled full‐length HBV DNA sequence and then analyzed using the DIG Luminescent Detection Kit for Nucleic Acids (Roche, Germany).

3. Results {#prca1926-sec-0180}
==========

3.1. ITRAQ Analysis of Differentially Expressed Proteins {#prca1926-sec-0190}
--------------------------------------------------------

We utilized iTRAQ proteomic methodology coupled with LC‐MS to identify differentially expressed proteins. HepG2 cells lines which harbored different functional domain of HBx were investigated. HepG2‐HBx and HepG2‐HBx‐Cm6 retained the ability to complement the augmentation effect on HBV replication, whereas HepG2‐HBx‐Cm16 did not. To increase the coverage of protein identification and/or the confidence of the data generated, samples were iTRAQ labeled as follows: HepG2‐HBx (119,121 tag), HepG2‐HBx‐Cm6 (113,115 tag), and HepG2‐HBx‐Cm16 (116,117 tag). A schematic flowchart of the iTRAQ method is shown in Figure [1](#prca1926-fig-0001){ref-type="fig"}.

![Schematic summary of experimental and data analysis process of the study.](PRCA-12-na-g001){#prca1926-fig-0001}

A total of 548 proteins were identified as being differentially expressed (over 1.5‐fold, *p* \< 0.05) among three cell lines (Figure [2](#prca1926-fig-0002){ref-type="fig"}A). These 548 proteins were classified into 24 functional categories by using cluster of orthologous groups (Figure [2](#prca1926-fig-0002){ref-type="fig"}B). To reduce false positives for the selection of differentially expressed proteins, 70 differentially expressed proteins were identified by double repetition among these three groups (119:116,121:117; 119:113,121:115; Tables [2](#prca1926-tbl-0002){ref-type="table-wrap"} and [3](#prca1926-tbl-0003){ref-type="table-wrap"}). Functional clustering analyses of the identified proteins from HepG2‐HBx, HepG2‐HBx‐Cm6, and HepG2‐HBx‐Cm16 cells are presented in Figure [2](#prca1926-fig-0002){ref-type="fig"}C.

![A) The number of differentially expressed proteins. B) Cluster of orthologous groups of proteins. Function classification of Homo Sequence. C) Functional clustering analysis of the identified proteins from HepG2‐HBx, HepG2‐HBx‐Cm6 ,and HepG2‐HBx‐Cm16 by double repetition.](PRCA-12-na-g002){#prca1926-fig-0002}

###### 

iTRAQ analysis of differentially expressed proteins between HepG2‐HBx and HepG2‐HBx‐Cm16

  No   Protein description                       Gene      Function                          Acce. no   Score   Mass     Cov    Fold change
  ---- ----------------------------------------- --------- --------------------------------- ---------- ------- -------- ------ -------------
  1    Glutathione S‐transferase A1              GST A1    Transferase                       P08263     138     33277    19.8   0.131
  2    Glutathione S‐transferase A2              GST A2    Transferase                       P09210     138     32949    19.8   0.131
  3    Alcohol dehydrogenase 4                   ADH4      Oxidoreductase                    P08319     110     53588    12     0.308
  4    Hydroxymethylglutaryl‐CoA synthase        HMGCS1    Lipid metabolic process           Q01581     161     66952    22.5   0.376
  5    Cathepsin D                               CATD      Lysosome                          P07339     1078    52338    41.5   0.461
  6    4‐hydroxyphenylpyruvate dioxygenase       HPD       Catabolism                        P327542    678     49712    39     0.468
  7    Superoxide dismutase                      SOD1      Oxidoreductase                    P00441     597     19804    22.7   0.473
  8    Cystatin‐B                                CSTB      Thiol protease inhibitor          P04080     273     14232    24.5   0.479
  9    Acyl‐CoA synthetase 4                     ACSL4     Lipid metabolism                  Q8TAF6     601     93710    23.5   0.48
  10   Cystatin‐C                                CST3      Thiol protease inhibitor          P01034     254     18451    18.5   0.498
  11   Coronin‐1A                                CORO1A    Structural component              P31146     114     58675    11.3   0.517
  12   Perilipin‐2                               PLIN2     Cellular component                Q99541     1119    58312    45.8   0.519
  13   Phenylalanine‐4‐hydroxylase               PAH       Oxidoreductase                    P00439     127     61773    10.2   0.532
  14   Peroxisomal multifunctional enzyme type   HSD17B4   Lipid metabolism                  P51659     959     97054    37.1   0.542
  15   Formimidoyltransferase cyclodeaminase     FTCD      Histidine metabolism              D3DSM8     234     70749    17.9   0.563
  16   Apolipoprotein A‐I                        APOA1     Lipid metabolism                  P02647     128     37756    22.5   0.586
  17   Putative hexokinase                       HKDC1     Glycolysis transferase            Q2TB90     103     123259   7.1    0.59
  18   6‐phosphofructokinase, liver type         PFKL      Glycolysis transferase            P17858     803     97322    24     0.6
  19   Acyl‐coenzyme A thioesterase 9            ACOT9     Acyl‐CoA metabolic process        Q9Y305     198     54973    26.1   0.605
  20   Dihydroxyacetone kinase                   DAK       Kinase, transferase               Q3LXA3     1331    68074    35     0.61
  21   Delta(24)‐sterol reductase                DHCR24    Lipid metabolism                  Q15392     151     70538    12     0.612
  22   Ribosomal protein S6 kinase alpha‐3       RSK2      Protein kinase                    B7ZB17     1282    97341    34.9   0.629
  23   Bile salt sulfotransferase                SULT2A1   Lipid metabolism                  Q06520     193     41534    31.9   0.641
  24   cAMP‐dependent protein kinase type I      PRKAR1A   Signal pathway                    P10644     523     50180    29.9   0.65
  25   Ribosomal RNA processing 1B               RRP1B     Poly(A) RNA binding               Q14684     329     105587   9.1    0.65
  26   Inter‐alpha (globulin) inhibitor H2       ITIH2     Serine protease inhibitor         A2RTY6     381     126903   17.8   0.665
  27   Targeting protein for Xklp2               TPX2      Apoptosis                         Q9ULW0     211     116648   13.8   1.518
  28   Dimethylarginine hydrolase 2              DDAH2     Hydrolase                         Q5SSV3     221     21790    22.9   1.592
  29   Transgelin‐2                              TAGLN2    Epithelial cell differentiation   P37802     186     26503    38.2   1.638
  30   Prostaglandin reductase 1                 PTGR1     Oxidoreductase                    Q14914     166     41620    14.6   1.646
  31   Major prion protein                       PRNP      Prion, cell cycle                 Q6FGR8     82      31156    11.9   1.68
  32   LIM domain and actin binding 1            LIMA1     Actin binding protein             Q9UHB6     162     108443   14.3   1.793
  33   Fascin1                                   FSCN1     Actin bundling protein            Q96IH1     1622    64551    47.6   1.822
  34   Actin binding LIM protein 1               ABLIM1    Actin binding protein             B3KSG3     272     71787    22.8   1.827
  35   Transgelin                                TAGLN     Epithelial cell differentiation   Q01995     992     28129    65.2   3.526
  36   Solute carrier family 2                   SLC2A1    Sugar transport                   Q0P512     468     59532    12.2   3.568
  37   Dipeptidyl peptidase 4                    DPP4      Cell adhesion                     P27487     251     101379   12.5   3.854
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###### 

iTRAQ analysis of differentially expressed proteins between HepG2‐HBx and HepG2‐HBx‐Cm6

  No   Protein description                               Gene name        Function                             Acce. no   Score   Mass     Cov    Fold change
  ---- ------------------------------------------------- ---------------- ------------------------------------ ---------- ------- -------- ------ -------------
  1    Alcohol dehydrogenase 4                           ADH4             Oxidoreductase                       P08319     110     53588    12     0.182
  2    Heat shock protein beta‐1                         HSPB1            Molecular chaperone                  P04792     438     25259    39     0.274
  3    Glypican‐3                                        GPC3             Protease inhibitor                   P51654     154     77193    11.6   0.313
  4    Claudin‐6                                         CLD6             Host--virus interaction              P56747     129     26280    5.5    0.422
  5    3‐oxo‐5‐beta‐steroid 4‐dehydrogenase              AKR1D1           Oxidoreductase                       P51857     160     44996    8.6    0.425
  6    CTP synthase 2                                    CTPS2            Synthase                             Q9NRF8     231     77880    15     0.48
  7    Liver carboxylesterase 1                          EST1             Transferase                          P23141     1014    74630    32.3   0.488
  8    Dimethylargininedimethylaminohydrolase 2          DDAH2            Hydrolase                            Q5SSV3     221     25551    19     0.527
  9    Glutathione S‐transferase A1                      GST A1           Transferase                          P08263     138     33277    19.8   0.549
  10   Glutathione S‐transferase A2                      GST A2           Transferase                          P09210     138     32949    19.8   0.549
  11   Cystatin‐C                                        CST3             Thiol protease inhibitor             P01034     254     18451    18.5   0.558
  12   Aldo‐keto reductase family                        AKR1B10          Cellular component                   O60218     155     48851    5.1    0.558
  13   Lysosomal‐associated membrane protein 1           LAMP1            Host--virus interaction              P11279     155     51147    4.8    0.558
  14   Mucosa‐associated lymphoid tissue protein1        MALT1            Ubl conjugation                      Q9UDY8     168     108963   10     0.575
  15   cAMP‐dependent protein kinase type I              PRKAR1A          Cellular component                   P10644     523     50180    29.9   0.601
  16   Putative uncharacterized protein                  DKFZp 779L0468   Other                                Q68DQ4     523     50146    29.9   0.601
  17   Aldo‐keto reductase family 1 member C2            AKR1C2           Lipid metabolism                     P52895     1325    45325    39.9   0.617
  18   SUB1 homolog                                      SUB1             Transcription                        P53999     534     20471    48.8   0.642
  19   Eukaryotic translation Initiation factor 4E       EIF4E            Translation                          P06730     173     30481    18.4   1.56
  20   Long chain fatty acid CoA                         ACSL3            Fatty acid metabolism                B2RBE0     532     99518    21.7   1.576
  21   Glucan‐branching enzyme                           GBE1             Glycogen biosynthetic process        E9PGM4     158     87015    9.1    1.586
  22   Insulin‐like growth factor binding protein 1      IGFBP1           Insulin‐like growth factor binding   P08833     286     31954    13.1   1.648
  23   Structural maintenance of chromosomes protein 2   SMC2             Nucleotide binding                   O95347     300     180803   15.5   1.681
  24   Zinc finger CCHC domain containing 3              ZCCHC3           Poly(A) RNA binding                  Q9NUD5     286     52299    18.6   1.705
  25   Gelsolin                                          GSN              Calcium ion binding                  P06396     237     94869    22.2   1.798
  26   Cholecystokinin                                   CCK              Hormone                              P06307     104     13688    7.8    1.875
  27   Histone H1.2                                      HIST1H1c         Chromatin DNA binding protein        P16403     1508    39604    30     2.042
  28   Histone H 1.4                                     HIST1H1E         Chromatin DNA binding protein        P10412     1488    41017    32.9   2.042
  29   RAD23 homolog B                                   RAD23B           UV excision repair protein           P54728     370     49590    23.2   2.193
  30   Alpha‐fetoprotein                                 AFP              Secreted protein                     P02771     350     85062    16.2   2.383
  31   Fatty acid binding protein 3                      FABP3            Transport                            P05413     138     19398    34.8   3.393
  32   Metallothionein‐1E                                MT1E             Zinc ion binding                     P04732     71      9887     32.8   4.027
  33   Fatty acid binding protein 1                      FABP1            Transport                            Q05CP7     768     22745    52.2   5.737

John Wiley & Sons, Ltd.

3.2. Validation of Differentially Expressed Proteins {#prca1926-sec-0200}
----------------------------------------------------

Differential expression levels of the proteins identified by the iTRAQ approach were validated using real‐time quantitative RT‐PCR analysis. Figure [3](#prca1926-fig-0003){ref-type="fig"}A shows the relative mRNA expression levels of ADH4, SOD1, CSTB, ACSL4, CORO1A, PLIN2, APOA1, RSK2, PRKAR1A, RRP1B, DPP4, and FABP1.The mRNA levels of ADH4, SOD1, CSTB, ACSL4, CORO1A, PLIN2, APOA1, RSK2, PRKAR1A, and RRP1B were downregulated in HepG2‐HBx‐Cm16 compared with HepG2‐HBx, whereas the mRNA levels of DPP4 and FABP1 were upregulated. These trends were similar with the protein expression levels determined by the iTRAQ approach.

![Evaluation of the differentially expressed proteins. A) Real‐time RT‐PCR detected the relative mRNA expression levels of ADH4, SOD1, CSTB, ACSL4, CORO1A, PLIN2, APOA1, RSK2, PRKAR1A, RRP1B, DPP4, and FABP1 in HepG2‐HBx, HepG2‐ HBx‐Cm6, and HepG2‐HBx‐Cm16 cells. \* *p *≤ 0.05 differ from HepG2‐HBx and HepG2‐HBx‐Cm16. B) Western blot for RSK2 in cell line HepG2, HepG2‐HBx, HepG2‐HBx‐Cm6, and HepG2‐HBx‐Cm16 cell. C) Representative MS/MS spectrum showing the peptides from RSK2 (peptide sequence: LTAALVLR).](PRCA-12-na-g003){#prca1926-fig-0003}

The MS/MS spectrum of p90 RSK2 (peptide sequence: LTAALVLR) is presented in Figure [3](#prca1926-fig-0003){ref-type="fig"}C. The ratio of 119:116 and 121:117 indicates the relative abundance of RSK2 protein in HepG2‐HBx compared to that in HepG2‐HBx‐Cm16 cells. Similarly, the ratio of 119:113 and 121:115 indicates the relative abundance of RSK2 protein in HepG2‐HBx compared to that in HepG2‐HBx‐Cm6 cells. When the same protein gave two relative quantitative ratios, the quantitation ratio from the experiment with the best *p*‐values was selected.

Figure [3](#prca1926-fig-0003){ref-type="fig"}B shows a representative Western blot analysis of RSK2 expression in four cell lines. RSK2 is expressed at higher levels in HepG2‐HBx and HepG2‐HBx‐Cm6, compared with HepG2 and HepG2‐HBx‐Cm16. HepG2‐HBx‐Cm6 harboring the HBx retained the ability to complement the augmentation effect, whereas HepG2‐HBx‐Cm16 did not. This indicates that the host protein RSK2 might play a role in HBx augmenting HBV replication.

3.3. Association of RSK2 With HBV Replication {#prca1926-sec-0210}
---------------------------------------------

RSK2 expression was silenced by siRNA in HepG2 and HepG2.2.15. (Figure [4](#prca1926-fig-0004){ref-type="fig"}A,B). As shown by Western blotting, RSK2 siRNA transfection significantly reduced RSK2 protein levels, whereas control siRNA has no effect. The effect of RSK2 siRNA transfection on HBV replication was explored further. The level of HBV replication intermediates in RSK2 siRNA‐transfected HepG2.2.15 cells was twofold lower than that in the controls. The levels of HBV DNA, HBcAg, HBsAg, and HBeAg were decreased 37.4, 34.0, 42.3, and 50.2, respectively, after silencing RSK2 in HepG2.2.15 (Figure [4](#prca1926-fig-0004){ref-type="fig"}A). This indicates that silence of RSK2 reduced HBV DNA replication and expression.

![Association of RSK2 in HBV replication and HBx augmenting HBV replication. A) Levels of RSK2, HBV DNA replication intermediates, HBcAg, HBsAg, and HBeAg in HepG2.2.15 and RSK2 siRNA‐transfected HepG2.2.15. B) RSK2 detected by Western blotting after siRNA transfection of HepG2 cells. C) Levels of HBV DNA RI, HBcAg, HBsAg, and HBeAg in HepG2 which were transfected with wild‐type HBV, HBx‐minus HBV, and HBx‐minus HBV plus ectopic expression of HBx plasmid. Data shown are the means ± SD. Statistical significance was examined by one‐way analysis of variance pairwise comparison. *p* \< 0.05 was considered statistically significant; \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001. RI: replication intermediates.](PRCA-12-na-g004){#prca1926-fig-0004}

3.4. Association of RSK2 in HBx Enhancing HBV Replication {#prca1926-sec-0220}
---------------------------------------------------------

As shown by Western blotting in Figure [4](#prca1926-fig-0004){ref-type="fig"}A, RSK2 siRNA transfection of HepG2 cells significantly reduced RSK2 protein levels. In HepG2 cells, the levels of HBV DNA replication intermediates synthesized from the HBx‐deficient HBV genome were twofold lower than levels synthesized from the wild‐type HBV genome. Furthermore, the decreased levels of HBV replication intermediates synthesized from the HBx‐minus HBV construct were restored to levels similar to that observed with the wild‐type construct by cotransfection of HBx expression plasmid (two‐ to threefold that of HBx‐deficient HBV). These results indicate that HBx has an augmentation role in HBV transcription and replication. In contrast, the levels of HBV replication intermediates synthesized from HBx‐minus HBV mutant genome were not restored to levels observed with wild‐type HBV by cotransfection of the HBx expression plasmid in RSK2 siRNA‐transfected HepG2 cells. The levels of HBV DNA (*p* \< 0.001), HBcAg (*p* \< 0.001), HBsAg (*p* \< 0.01) and HBeAg (*p* \< 0.001) shows the same trend as HBV DNA replication intermediates (Figure [4](#prca1926-fig-0004){ref-type="fig"}C).

4. Discussion {#prca1926-sec-0230}
=============

It has been demonstrated that HBx plays an important role in augmenting HBV replication by transcriptional transactivation function in vivo and in vitro. However, the underlying molecular mechanism by which HBx enhances HBV replication are not fully understood. The transcriptional transactivation function of HBx is dependent on pleiotropic protein--protein interactions. The "key" host proteins involved in HBx enhancement of HBV transcription and replication have not been identified. Clarification of the roles of host proteins in HBx augmentation of HBV transcription and replication would help elucidate the HBV pathogenicity mechanism.

In this study, we utilized iTRAQ proteomic methodology coupled with LC‐ESI‐MS/MS to identify and quantitate differentially expressed proteins among HepG2 cell lines stably harboring different functional domains of HBx. Seventy differentially expressed proteins were identified among HepG2‐HBx, HepG2‐HBx‐Cm6, and HepG2‐HBx‐Cm16 by two duplicate groups. Many of them, including ADH4, SOD1, CSTB, ACSL4, CORO1A, PLIN2, APOA1, RSK2, PRKAR1A, RRP1B, DPP4, and FABP1, were confirmed by qRT‐PCR analysis. RSK2 was expressed at higher levels in HepG2‐HBx and HepG2‐HBx‐Cm6, compared with HepG2‐HBx‐Cm16 and HepG2. These results are consistent with the protein expression level determined by the iTRAQ approach. Tao Zhang et al.[10](#prca1926-bib-0010){ref-type="ref"} performed an integrated proteomics and bioinformatics analysis of HBx interacting proteins. They also identified RSK2 as a novel interactor. Collectively, these data provide evidence that the iTRAQ reagents labeling method for large scale protein quantification is powerful and reliable for HBV‐related investigations.[11](#prca1926-bib-0011){ref-type="ref"}

The RSK2 siRNA‐transfected HepG2.2.15 cells showed decreased HBV DNA, HBsAg, and HBeAg levels. This indicates that RSK2 is involved in regulating HBV replication. HBx augments HBV replication and expression, because an HBx‐minus HBV mutant genome led to decreased levels of HBV replication intermediates, HBsAg , and HBeAg. These decreases can be restored to levels similar to wild‐type HBV by transient ectopic expression of HBx. After silencing RSK2 expression, the levels of HBV replication intermediates, HBsAg and HBeAg synthesized from the HBx‐minus HBV mutant genome, were not restored to levels observed in wild‐type HBV by transient ectopic expression of HBx. This indicates that RSK2 plays an important role in HBx by augmenting HBV replication. RSK2 was identified as a novel host protein in HBx augmenting HBV replication.

The RSK (90 kDa ribosomal S6 kinase) family comprises a group of highly related serine/threonine kinases that regulate diverse cellular processes, including cell growth, proliferation, survival and motility.[12](#prca1926-bib-0012){ref-type="ref"} Members of this family, which are downstream effectors of the Ras/ERK signaling pathway, includes four vertebrate isoforms (RSK1, RSK2, RSK3, and RSK4).[13](#prca1926-bib-0013){ref-type="ref"} RSK2 was identified as an important effector of ERK in global transcriptional regulation. Indeed, activated RSK2 was shown to phosphorylate several transcription factors including AP‐1, CREB, c‐Fos, c‐Jun, and others, some of which contribute to the IEG (immediate‐early gene) response or are IEG products themselves.[14](#prca1926-bib-0014){ref-type="ref"} Some transcription factors play an important role in the transcription of retrovirus. The previous studies demonstrated that HBx transcriptional activity is also linked to its capacity to stimulate MAPKs and JAK/STAT signaling pathways.[2](#prca1926-bib-0002){ref-type="ref"} Despite the fact that RSK2 is a member of MAPKs signaling pathways, no study has investigated the relationship between HBx and RSK2. RSK2 has been implicated in other viral infections, such as HIV, HCV, and influenza.[15](#prca1926-bib-0015){ref-type="ref"}, [16](#prca1926-bib-0016){ref-type="ref"} Kaposi\'s sarcoma‐associated herpes virus ORF45 mediates transcriptional activation of the HIV‐1 long terminal repeat via RSK2.[17](#prca1926-bib-0017){ref-type="ref"}, [18](#prca1926-bib-0018){ref-type="ref"}, [19](#prca1926-bib-0019){ref-type="ref"} HIV Tat protein interacts with RSK2 and activated RSK2 kinase activity in cells, and might serve to induce early changes in the chromatin organization of the HIV LTR.[20](#prca1926-bib-0020){ref-type="ref"} The regulation and function of RSK2 may explain its role in HBx enhancement of HBV replication.

In this study, pathway analysis also revealed that HBx‐related differentially expressed proteins are associated with lipid metabolism. Previous studies indicated that HBx‐induced abnormal lipid metabolism of hepatoma in hepatocarcinogenesis.[21](#prca1926-bib-0021){ref-type="ref"} This indicates that HBx induces abnormal lipid metabolism to meet the bioenergetic demands of extreme cell growth and proliferation. Another study showed that fatty acids increase HBx stabilization and HBx‐induced inflammatory gene expression.[22](#prca1926-bib-0022){ref-type="ref"}The differentially expressed protein apolipoprotein A‐I (apoA‐I), which has a specific role in lipid and cholesterol metabolism, has been proved to be a novel interactor with HBx and may influence HBV secretion.[10](#prca1926-bib-0010){ref-type="ref"}

In conclusion, RSK2 was identified as a novel host protein in HBx augmenting HBV replication by iTRAQ‐based quantitative comparative proteomics. These results may help to better understand the HBV pathogenicity mechanism.
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